恆譽環保(688309.SH):豐創生物等股東擬減持合計不超6%股份
格隆匯7月29日丨恆譽環保(688309.SH)公佈,因經營期限到期或自身經營需要等原因,公司股東豐創生物、豐德瑞、木利民、桑綠蓓擬通過集中競價和大宗交易的方式減持合計不超過所持公司股票4,800,560股,即不超過公司總股本的6.00%。
其中,通過集中競價交易方式減持的,自公吿披露之日起15個交易日後的六個月內進行,任意連續90日內減持股份的總數不超過公司總股本的1%;通過大宗交易方式減持的,自公吿披露之日起3個交易日後的六個月內進行,任意連續90日內減持股份的總數不超過公司總股本的2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.